"10.1371_journal.pone.0093179","plos one","2014-03-25T00:00:00Z","Laurent Sakka; Nathalie Delétage; Fabrice Lalloué; Amélie Duval; Jean Chazal; Jean-Jacques Lemaire; Annie Meiniel; Hubert Monnerie; Stéphane Gobron","Image-Guided Clinical Neuroscience and Connectomics, EA7282, Faculté de Médecine, Université dAuvergne, Clermont-Ferrand, France; Neuronax, Biopôle Clermont-Limagne, Saint-Beauzire, France; Service de Neurochirurgie, Centre Hospitalier et Universitaire de Clermont-Ferrand, Clermont-Ferrand, France; Homéostasie Cellulaire et Pathologies, EA3842, Faculté de Médecine, Limoges, France; Laboratoire GReD/Inserm U 110/CNRS, UMR 629, Faculté de Médecine, Université dAuvergne, Clermont-Ferrand, France; Department of Neurology, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: LS SG ND. Performed the experiments: LS SG ND AD. Analyzed the data: LS SG ND HM FL. Contributed reagents/materials/analysis tools: JJL JC AM. Wrote the paper: LS SG.","NX210 is a Neuronaxs candidate drug in the course of development. S. Gobron is the Chief executive officer of Neuronax, and Nathalie Delétage and Amélie Duval are employed by Neuronax. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","03","Laurent Sakka","LS",9,TRUE,3,4,5,2,TRUE,TRUE,FALSE,0,NA,FALSE
